Our research results are published and made publicly available.
Learn, how AGAH is organized and works
Our international partners
Become a member
What is the AGAH?
The Association for Applied Human Pharmacology (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e.V. - AGAH) as a specialist medical-academic organisation focuses on exploratory medicinal product development and human pharmacological research.
AGAH sees itself as an organisation for everyone dealing with clinical pharmacological test programs, studies in the target population in early-stage medicinal product development and translational topics.
AGAH is a member of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - AWMF) and it cooperates with the german society for experimental and clinical pharmacology and toxicology (Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)). Further it cooperates with the French Club Phase I and the the American College of Clinical Pharmacology (ACCP).
Progress through exchange, dialogue and cooperation - this is how AGAH sees itself today and in the future.
Focus of our Work
Our work focuses on the conception and planning of clinical pharmacological trials, their approval and testing processes, as well as their practical implementation and evaluation. Apart from the traditional areas of pharmacokinetics and pharmacodynamics, it covers the inclusion of biomarkers in clinical trials and the consideration of statistical and pharmacometric methods in the planning and evaluation of trials.
Researchers and developers from universities, (bio)pharmaceutical industry, contract research organisations, authorities and ethics committees come together in the AGAH. The interfaces to the preclinical stage and the later phases of clinical trials are not excluded but consciously and actively integrated into our academic work.
We are conscious of our special responsibility, which comes with the implementation of research projects in humans, especially when the trial participants do not gain any personal benefit of participating in the trials – a particular type of ethical challenge, especially in the early phases of clinical trials.
High-quality research projects with particular attention paid to safety aspects are therefore most important for the people participating as test subjects in these trials, but also for the knowledge gained for subsequent application in treatment. As an academic organisation we strive to make a contribution here.
Responsible for the people
International context
Progress through cooperations: Our partner organisations
We started our work as a national organisation over 25 years ago and have moved with the times – today research is international, cross-border and varied; for example, the AGAH is a founding member of EUFEMED (European Federation of Exploratory Medicines Development), a consortium of specialist organisations with the same orientation for discussing and promoting early-stage medicinal product development at a European level.
Progress through exchange, dialogue and cooperation - this is how AGAH sees itself today and in the future.
